Gain access to Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study ACCESS PHARMACEUTICALS, INC. , today announced that it has completed enrollment and evaluation of the last additional cohort of sufferers in the ongoing scientific research of ProLindac as a monotherapy in ovarian cancer patients who’ve received at least two prior platinum structured treatment regimens. The additional cohort of 8 patients received the ProLindac batch made by a better scalable process, which is used on a larger scale for future commercial and clinical supplies.Losing one’s way driving home from a familiar area, such as the grocery store, isn’t. When dementia-like symptoms start to become a concern, it is time to see a physician. Memory reduction and various other dementia symptoms have many causes, so diagnosis can be a challenge. However, early and accurate analysis allows for treatment that might help reverse, lessen or delay the progression of symptoms.
Acetylsalicylic acid slows decline in brain capacity among the elderly A daily dose of acetylsalicylic acid equivalent to a fourth of an aspirin may slower the decline in intellectual capacity among elderly people with high cardiovascular risk. That is demonstrated in a scholarly study by Sahlgrenska Academy, University of Gothenburg, Sweden.